statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Latest Ratings for OVID
 DateFirmActionFromTo Aug 2021CitigroupMaintainsNeutral Apr 2021Cantor FitzgeraldDowngradesOverweightNeutral Dec 2020CitigroupDowngradesBuyNeutral
 View More Analyst...

Cracking The Code: Understanding Analyst Reviews For Ovid Therapeutics

NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies...

Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Marinus Comments on patent challenge by Ovid Therapeutics

This is a Bullish indicator signaling OVID's price could rise from here. Traders may explore going long the stock or buying call options...

Ovid Therapeutics (OVID, $3.2) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 22, 2024

This is a signal that OVID's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Ovid Therapeutics (OVID, $3.07) RSI Indicator left the oversold zone on March 21, 2024

In a report released yesterday, Ritu Baral from TD Cowen maintained a Buy rating on Ovid Therapeutics (OVID Research Report). The company's share...

TD Cowen Sticks to Its Buy Rating for Ovid Therapeutics (OVID)

Two pivotal Phase 3 clinical trials studying soticlestat as a treatment for Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) completed enrollment; Takeda anticipates topline data readout by or...

Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results

Ovid Therapeutics Inc To Host Research & Development (R&D) Day Transcript

Ovid Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript

Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.

Watchers	5,750
52-Wk Low	$2.57
52-Wk High	$4.14

Volume	41,401.00
52-Wk High	$4.14
52-Wk Low	$2.57

OVID Ovid Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals

Sentiment

Message Volume

Community